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Abstract
Fo¨rster resonance energy transfer (FRET) is a phenomenon widely utilized in biomedical research of macromolecular
interactions. In FRET energy is transferred between two fluorophores, the donor and the acceptor. Herein we describe a
novel approach utilizing time-resolved FRET (TR-FRET) for the detection of antibodies not only in a solution-phase
homogenous assay but also in single- and two-step solid-phase assays. Our method is based on the principle that the Y-
shaped immunoglobulin G molecule is able to simultaneously bind two identical antigen molecules. Hence, if a specific IgG
is mixed with donor- and acceptor-labeled antigens, the binding of antigens can be measured by TR-FRET. Using donor- and
acceptor-labeled streptavidins (SAs) in conjunction with a polyclonal and a monoclonal anti-SA antibody we demonstrate
that this approach is fully functional. In addition we characterize the immune complexes responsible for the TR-FRET signal
using density gradient ultracentrifugation and solid-phase immunoassays. The homogenous TR-FRET assay described
provides a rapid and robust tool for antibody detection, with a wide potential in medical diagnostics.
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Introduction
Fo¨rster resonance energy transfer (FRET) is a process in which
a donor molecule in excited state transfers its excitation energy
through dipole-dipole coupling [1] to an acceptor fluorophore,
when the two are brought into close proximity (typically less than
10 nm) [2,3]. Upon excitation at a characteristic wavelength the
energy absorbed by the donor is transferred to the acceptor, which
in turn emits the energy. The level of light emitted from the
acceptor fluorophore is proportional to the degree of donor-
acceptor complex formation [4]. FRET between chromophores is
characterized by Fo¨rster radius (R0), the distance at which the
efficiency of FRET is 50% [5]. This phenomenon has been
applied, among others, to study of protein-protein interactions,
antigen-antibody binding, ligand-receptor interactions, DNA
hybridization and DNA-protein binding [2,6–11].
Many molecules present in biological fluids such as serum are
naturally fluorescent, thus limiting the use of conventional
fluorophores. The interfering autofluorescence can be minimized
by utilizing long-lived fluorophores and time-resolved (TR; delay
between excitation and emission) detection. Time-resolved fluo-
rometry (TRF) relies on the long fluorescence emission half-life of
lanthanides, rare earth elements such as europium (Eu) and
terbium (Tb) [12–16]. TR-FRET unites the TRF and FRET
principles. In TR-FRET, chelated or cryptic lanthanides are
typically used as donors for acceptors such as Alexa FluorsTM or
cyanine dyes (e.g. Cy5).
Most serodiagnostic assays, such as enzyme-linked immunosor-
bent assay (ELISA), are heterogeneous approaches with several
steps of washing and reagent incubations. Such methods tend to
consume time, labour and cost. To overcome such issues, TR-
FRET-based homogeneous assays have been employed widely in
research and diagnosis to detect e.g., antibodies, disease markers
and receptor-ligand binding. [17–20].
The immunoglobulin G (IgG) molecule by nature is bivalent,
that is, each IgG molecule can bind two identical antigens through
its Fab arms. The hinge regions between the Fab and Fc parts are
relatively flexible (with slight differences between different IgG
subclasses) allowing the movement of the two Fab arms towards
and away from each other [21–23]. Due to the flexibility of IgG
molecule the antigens bound to its Fab arms can be brought into
close proximity to each other. We reasoned that if one of the
antigens is labeled with a donor fluorophore and the other with an
acceptor fluorophore, the antigen binding (in the 50% cases
forming a heterologous donor-acceptor pair) could be measured
utilizing TR-FRET. Since TR-FRET minimizes background
autofluorescence, this approach should enable the detection of
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specific antibodies directly from biological fluids such as serum or
even a blood droplet.
In this report we provide proof-of-principle for a TR-FRET
based homogenous immunoassay using donor- and acceptor-
coupled streptavidins (SAs) as a model system in conjunction with
polyclonal and monoclonal anti-SA antibodies at various concen-
trations. As the chosen antigen is tetrameric by nature, we were
also interested in studying the molecular determinants of the
FRET-inducing complexes. Therefore we characterized the
antigen-antibody complexes accounting for the TR-FRET signal
using density gradient ultracentrifugation.
Materials and Methods
Proteins and Antibodies
Alexa FluorTM 647 (AF647) and europium-W1024-chelate -
labeled SA (AF647-SA and Eu-SA) used as antigens in our assays
were ordered from Invitrogen and PerkinElmer, respectively.
Monoclonal antibody (MAb) against SA (mouse IgG2, clone
S3E11, 6.1 mg/ml) was from Thermo Scientific (Pierce Protein
Biology Products). IgG fractions of rabbit anti-SA sera (from
Abcam Ltd 1 mg/ml and Springbioscience Inc 0.2 mg/ml) were
used in our assays as representatives of polyclonal antibodies
(PAbs). The antibody from Springbioscience was used only when
determining the sizes of the immune complexes. IgG fraction of
rabbit antiserum against glutathione-S-transferase (GST, Milli-
pore, 0.5 mg/ml) was used as a control for the anti-SA antibodies.
Horseradish peroxidase (HRP) labeled secondary antibodies,
polyclonal swine anti-rabbit IgG and polyclonal rabbit anti-mouse
IgG were from Dakocytomation (Agilent Technologies). Protein A
(2 mg/ml) was from GE Healthcare and bovine serum albumin
(BSA) from Sigma-Aldrich.
Generation of anti-SA Fab fragments. The anti-SA MAb
(S3E11) was fragmented using papain. Papain 25 mg/ml, 40 U/
mg, (P3125, Sigma-Aldrich) was diluted 1 to 10 in 100 mM L-
cysteine (in PBS, pH 7.4) and preactivated by 15 min incubation
at RT. Anti-SA MAb was diluted 1 to 3 in reaction buffer (10 mM
L-cysteine and 10 mM EDTA in PBS) yielding a 2 mg/ml
antibody solution. Preactivated papain was further diluted 1 to 100
in reaction buffer. The cleavage reaction was set up by mixing 1
part of papain solution with 1 part of diluted antibody. The
cleavage was carried out at 37uC for 4 h, after which papain was
inactivated by addition of 0.3 M iodoacetamide (in PBS) to reach
final concentration of 30 mM.
Adsorption with GammabindTM Plus SepharoseTM (GE
Healthcare) was used to remove intact IgG molecules and to
roughly separate the cleavage products (Fab and Fc parts) from
each other. Briefly, GammabindTM beads were equilibrated to
PBS+(PBS with additional 150 mM NaCl and 0.01% of Tween
20), mixed with the reaction mixture and incubated 15 min at RT.
The beads were sedimented by centrifugation (5006g, 2 min) and
the supernatant recovered. The beads were washed twice with
150 ml of PBS+and the resulting supernatants were pooled
together with the initial supernatant. The supernatant pool
containing the Fab fragments and inactivated papain was
concentrated and the buffer exchanged to PBS using Amicon
Ultra 10 kDa centrifugal filter units (Millipore) according to
product instructions. After buffer exchange the protein concen-
tration was quantified using BCA Protein Assay kit (Pierce)
according to manufacturer’s instructions. The final protein
concentration of Fab containing fraction was 0.65 mg/ml. The
success of cleavage and purification was analyzed by separating an
aliquot of GammabindTM beads and concentrated Fab fragments
on non-reducing 8% SDS-PAGE. The proteins were stained with
Coomassie Brilliant Blue and detected by scanning the gel at
700 nm in Odyssey Infrared Imaging System.
Enzyme-linked Immunosorbent Assay (ELISA)
A twofold dilution series (from 1/400 to 1/409 600,
corresponding to 17 nM to 0.016 nM) of both anti-SA PAb and
MAb (initial IgG concentration for both 1 mg/ml, roughly
corresponding to 6.6 mM) was done in Tris-buffered saline
(TBS, 50 mM Tris-HCl pH 7.4 and 150 mM NaCl) containing
0.2% BSA (TBS-BSA). 100 ml of each dilution was pipetted into
wells of SA coated microwell strips (96-well format, BioBind
assembly, Thermo Electron Oy) followed by one hour incubation
at 37uC. TBS-BSA was used as a negative control. The wells were
washed four times with 200 ml of TBS, 100 ml/well secondary
antibody added (anti-rabbit-HRP and anti-mouse-HRP, both
diluted 1:500 in TBS-BSA) followed by 1 hour incubation at
37uC. After four washes with TBS (200 ml each) 100 ml of HRP
substrate (Dakocytomation) was added and the plate was
incubated 20 min at RT. The reaction was terminated by addition
of 0.5 M H2SO4 (100 ml/well) and the results were read
(absorbance at 492 nm). This experiment was repeated in total
three times with similar results.
SA-ELISA was also used to test the ability of the Fab fragments,
cleaved from mouse anti-SA antibody, to bind SA. Briefly, a
dilution series (1:100–1:6400) of the Fab solution and intact anti-
SA MAb (40 nM to 0.625 nM) were pipetted on wells of
streptavidin-coated 96-well plates (BioBind assembly, Thermo
Electron Oy) in duplicate. After 45 min incubation at 37uC the
plate was washed three times with PBS-T (PBS+0.05% Tween 20)
and 1 to 1000 diluted HRP-labeled rabbit anti-mouse antibody
was added followed by 45 min incubation at 37uC. The plate was
then washed three times with PBS-T followed by addition of TMB
substrate solution (Sigma-Aldrich). The reaction was stopped by
addition of 50 ml 0.5 M H2SO4 and the results were read at
450 nm. The experiment was performed in duplicate.
TR-FRET Assays
After optimization, the basic protocol was: Eu-SA, AF647-SA
and antibodies were diluted in TBS-BSA. Throughout this report,
the concentrations of Eu-SA and AF647-SA are given separately
(total SA concentration is the sum of the two). All experiments
were performed in duplicate and repeated several times; repre-
sentative results are shown. TR-FRET values were measured with
Wallac Victor2 fluorometer (PerkinElmer) by excitation at 320 nm
followed by a delay of 70 ms before recording fluorescent counts
for 100 ms with 615 nm (Eu) and 665 nm (AF647) emission filters.
To take into account the emission of Eu at 665 nm the measured
TR-FRET values were normalized according to the following
equation: AF647N=AF647–k*Eu, where AF647N=normalized
AF647 fluorescent counts, AF647= unnormalized A647 counts (at
655 nm), k =Eu emission at 665 nm/Eu emission at 615 nm and
Eu=Eu fluorescent counts (at 615 nm). The constant k was found
to be independent of Eu-SA concentration whereby a value of
0.001342 (average of AF647- to Eu-counts in Eu-SA dilutions of
1:1000 to 1:8000) was used in subsequent calculations. With
reactions having low AF647 counts and high Eu counts, the
normalization would occasionally result in a negative value; in
these cases we used the buffer background (typically 3 to 10
counts) as the final value.
Solution-phase homogenous assay. In the solution-phase
TR-FRET assays, the final reaction mixture (20 ml) consisted of
10 ml of the antigen mix and 10 ml of antibody solution that were
dispensed onto a 384-well microplate. The suitability of two
microplates (ProxiPlate-384 Plus F, Black 384-shallow well
FRET Serodiagnostics
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Microplate, and OptiPlate-384, White Opaque 384-well Micro-
plate, both from PerkinElmer) was tested. Irrespective of the plate
type similar results were obtained; thus to minimize reagent use in
the assays, we chose the Black Proxiplate due to its smaller well
size.
To explore the prerequisites of FRET-pair formation with the
chosen antigens and antibodies, we cross-titrated the antigens at
concentrations of 0.5 nM, 1.0 nM, 2.0 nM, 4.0 nM and 8.0 nM
and antibodies at concentrations of 66.6 nM, 33.33 nM, 16.7 nM,
8.5 nM and 4.16 nM for the anti-SA MAb and PAb, and
33.33 nM, 16.7 nM, 8.5 nM, 4.16 nM and 2.08 nM for the anti-
GST PAb. To test the optimal ratio of the labeled antigens we kept
the Eu-SA concentration constant at 4 nM and varied the AF647-
SA concentration in the range of 16 nM, 8 nM, 4 nM, 2 nM and
1 nM separately with PAbs and MAb. Additionally, we studied the
effect of reaction time on the TR-FRET responses by measuring
the plates after incubation at 4uC or RT for 15 min to 24 h. The
experiments were performed in duplicate and repeated several
times with similar results.
To test the effect of dissociating agents sodium dodecyl sulfate
(SDS) and urea on formation of TR-FRET positive immune
complexes, we diluted the antigens and IgG (anti-SA PAb) in TBS-
BSA containing these agents at various concentrations (2 M, 1 M,
0.5 M and 0.25 M for urea and 0.5%, 0.25%, 0.1% and 0.05%
for SDS) prior to dispensing onto 384-well plate. The antigen
concentration was kept constant (4 nM Eu-SA and 4 nM AF647-
SA) while the antibody was diluted serially (20 nM, 10 nM and
5 nM of total IgG). The experiments were performed in duplicate
and repeated several times, representative results shown.
The ability of Fab fragments to induce TR-FRET was tested by
mixing various concentrations (120 nM to 7.5 nM) of Fab
fragments with Eu-SA and AF647-SA (both 8 nM).
Solid-phase TR-FRET assays. Black Optiplate-384 F HB
(Perkin Elmer) microplate was coated with protein A at 2 mg/ml
dilution in TBS (optimized by titration) overnight at room
temperature (RT), blocked three times 10 minutes with TBS-
BSA. Washes were performed four times with TBS. Subsequent
reactions occurred in TBS-BSA at 37uC.
In single-step assays the final reaction mixture (40 ml) consisted
of 20 ml of antigen mix and 20 ml of polyclonal anti-SA dilution.
Final concentrations were 4 nM for both Eu-SA and AF647-SA
and 66.6 nM to 4.16 nM for anti-SA. After one hour the TR-
FRET values were measured. The second measurement was done
after washings. The experiments were performed in duplicate and
repeated several times.
In two-step assays 40 ml of polyclonal anti-SA (66.6 nM to
4.16 nM) was added into wells. After 1 hour the wells were washed
and the antigen mix (4 nM Eu-SA+4 nM AF647-SA) was added.
TR-FRET values were measured after one hour, and after
washings. The experiment was performed in duplicate and
repeated multiple times.
Density Gradient Ultracentrifugation
Continous sucrose density gradients were generated as de-
scribed [24]. Briefly, 0–70% sucrose gradient was generated by
layering sucrose solutions (70%, 60%, 50%, 40%, 30%, 20%, 10%
and 0%) on top of each other in 14689 mm Ultra-ClearTM tubes
(Beckman Coulter). The gradient was allowed to linearize by
keeping the tubes at 4uC overnight prior to centrifugation. Four
antigen-antibody combinations were tested: two antigen concen-
trations for the monoclonal (10 nM AF647-SA+10 nM Eu-SA
together with 20 nM yielding a molar ratio of 1:1:2, and 2.5 nM
AF647-SA+2.5 nM Eu-SA together with 20 nM of antibody
yielding a molar ratio of 1:1:8), and two different polyclonal
antibodies (20 nM each, Abcam; Springbioscience) with the
antigens at 6.6 nM (AF647-SA+Eu-SA) yielding a molar ratio of
3:1:1 (and approximately 1:1:1 of specific IgG versus Eu- and
AF647-SA). The samples containing the antigen-antibody com-
plexes were separately layered on top of the density gradient and
ultracentrifugation (40 000 rpm, 24 h, 5uC) was carried out in
SW41 rotor (Beckman Coulter). Fractions of ,300 ml were
collected on a 96-well plate from the bottom of the tube, and
the sucrose concentrations were determined using a refractometer.
Analysis of Protein Complexes in Density Gradient
Fractions
Antibodies in the fractions were detected by ELISA. Briefly,
10 ml of each fraction was mixed with 90 ml of 0.1 M Na2HCO3
(pH 9.3), pipetted onto 96-well plates and incubated 2 h at 37uC.
The plates were blocked with BSA (2 mg/ml in PBS) for 30 min.
After blocking, the plates were washed once with PBS-T
(PBS+0.05% Tween-20). 100 ml of HRP-labeled secondary (anti-
rabbit or anti-mouse) antibody diluted 1 to 1000 in PBS-T was
added for 1 h at 37uC. After incubation the wells were washed
four times with PBS-T and 100 ml of 3,39,5,59-tetramethylbenzi-
dine (TMB) substrate solution (Sigma Aldrich) was added. The
reaction was stopped by addition of 50 ml of 0.5 M H2SO4 and the
results were read at 450 nm.
The fractions containing the TR-FRET positive immunocom-
plexes were determined by pipetting 20 ml of each fraction onto a
microplate (ProxiPlate-384 Plus F, Black 384-shallow well
Microplate, PerkinElmer) in duplicate, and the TR-FRET values
were recorded using Wallac Victor2 fluorometer (PerkinElmer).
Determination of Molecular Weight from Sucrose
Concentration
The molecular weights of the protein complexes were deter-
mined using precalculated tables [25] for known sucrose
concentrations, as described [26].
Results
Determination of the Detection Limits for Anti-SA
Antibodies in ELISA
We used SA-coated plates to determine the detection limits for
the anti-SA monoclonal antibody (MAb) and polyclonal antibody
(PAb, rabbit IgG fraction, Abcam Ltd) in ELISA. Additionally, we
aimed to get an estimate for the concentration of specific IgG in
the IgG fraction of the PAb. The anti-SA antibodies were titrated
in twofold steps, in order to determine the highest dilution that
produces a signal higher than background. This dilution was found
to be 1:409 600 for MAb and 1:101 200 for PAb (Fig. 1a). By
comparing these end point titers, we conclude that the PAb
contains approximately 25–30% of specific IgG. We use this
estimate throughout this manuscript and indicate this number in
brackets under the whole IgG concentration in figures where
applicable.
As an additional control for the downstream assays we prepared
Fab fragments from anti-SA MAb by papain cleavage. After
cleavage, the Fab fragments were analyzed by SDS-PAGE
separation (see Fig. S1). The preparation was shown to be free
from intact IgG but did contain trace amounts of Fc parts and
inactivated papain. As shown in Fig. 1b the Fab fragments were
still capable of binding to SA-coated surface. Subsequently, the
optimum dilutions of the anti-SA Fab in relation to the intact anti-
SA MAb were assessed from the ELISA result (Fig. 1b). The
FRET Serodiagnostics
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partially purified Fab fragments were used as control in our TR-
FRET assays.
Antibody-induced TR-FRET of Donor- and Acceptor-
labeled Antigens
To assess whether an IgG molecule can induce TR-FRET
signal via cross-linking donor- and acceptor-labeled antigens,
signals induced by antigen-specific vs. unrelated antibodies were
compared. Mixtures of Eu- and AF647-labeled SA (in equimolar,
serially declining concentrations) were combined with serial
dilutions of polyclonal IgG from rabbits immunized either with
specific (SA) or control (GST) antigens. Our first experimental set-
up was a homogenous, solution-phase assay depicted in Fig. 2A.
With the labeled antigens both at 8 nM, the specific IgG induced
TR-FRET signal dose-dependently along with antibody concen-
tration (Fig. 3A). At each antibody dilution the TR-FRET signal
was proportional to the concentration of the antigen pair. In all,
the signal backgrounds in the absence of SA-specific IgG
accounted for approximately one tenth of the antibody-induced
signals (Fig. 3A). In contrast, the control IgG (anti-GST) showed
no dose-dependence (Fig. 3B) in signals that were comparable to
the low antibody-free backgrounds of Fig. 3A. Also the monoclo-
nal anti-SA antibody induced dose dependent TR-FRET signals,
similarly to the polyclonal anti-SA (Fig. 3C).
Furthermore to confirm that the observed TR-FRET signals
indeed are induced by donor- and acceptor-labeled antigens
brought into close proximity via bivalent interaction with anti-SA
MAb, a set of control experiments were performed using anti-SA
Fab fragments. Various amounts of Fab fragments (dilution series
from 120 nM to 7.5 nM) were mixed with Eu-SA and AF647-SA
(both at 8 nM) and the resulting TR-FRET signals were compared
to those induced by intact MAb. As shown in Fig. 3D, the Fab
fragments failed to induce TR-FRET signals higher than
background, while a typical dose depended signal increase was
seen with the intact anti-SA MAb (Fig. 3C).
Moreover, as most of the background is actually not TR-FRET-
derived but comes from spillover of Eu fluorescence into the
wavelength of measurement (665 nm), we normalized our TR-
FRET assay data in this regard (see Materials and Methods). The
normalized data are shown in the right-hand panel of Fig. 3, aside
of the original (uncorrected) data in the left. As apparent in e.g.
Fig. 3B, this elimination of fluorescence spillover brought the
background to less than 2% of original, i.e, from ,500 units (seen
with the highest concentration [8 nM] of fluorescent antigens) to
,10 units.
Figure 1. End point titration of the antibodies and testing of Fab fragments. A) Polyclonal antibody versus monoclonal antibody end point
titration (17 nM to 0.016 nM) using ELISA. B) A dilution series (0.09 nM to 120 nM) of Fab fragments was tested in SA-ELISA, using monoclonal
antibody (0.03 nM to 40 nM) as control. Error bars are 6 standard deviation calculated from parallel wells.
doi:10.1371/journal.pone.0062739.g001
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Figure 2. A schematic overview of the experimental procedures. A) Solution-phase assay setup. All reagents were pipetted onto a 384-well
plate and the TR-FRET signal read directly. B) One-step solid-phase assay. The antigen mixture and the antibody pipetted onto protein A coated wells
and the TR-FRET signal is measured directly (measurement 1) and after replacing the mixture with TBS (measurement 2). C) Two-step solid-phase
assay. In the first step the antibody was allowed to bind to a protein A coated well. In the second step equimolar antigen mixture was added. The TR-
FRET signal was measured directly after antigen addition (measurement 1) and after replacing the antigen mixture with TBS (measurement 2).
doi:10.1371/journal.pone.0062739.g002
FRET Serodiagnostics
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e62739
FRET Serodiagnostics
PLOS ONE | www.plosone.org 6 May 2013 | Volume 8 | Issue 5 | e62739
Not only the normalized but also the original data of Fig. 3A
point to a broad dynamic range of the solution-phase assay; as
apparent with the higher concentrations of fluorescent antigens (4
and 8 nM), all dilutions of polyclonal anti-SA IgG emerged
distinctly from background. By comparing the end-point dilutions
of ELISA and TR-FRET assay (,1:400 000 and 1:1600 for MAb,
respectively), we conclude the ELISA to be approximately 250-
fold more sensitive than this first generation TR-FRET assay.
Optimal Ratio of Donor- and Acceptor-labeled Antigens
To determine the optimal ratio of donor- vs. acceptor-labeled
antigens, we cross-titrated the polyclonal anti-SA IgG with the Eu-
SA and AF647-SA in many different ratios. The antibodies in four
dilutions were combined with an antigen mix containing Eu-SA
invariably at 4 nM and AF647-SA at 1 to 16 nM. Fig. 4 with
normalized TR-FRET signals shows the best signal to noise
relation. With PAb the optimum was at or near equimolar ratio of
donor- and acceptor-labeled antigens (Eu:AF647= 4:8 or 4:4),
while with MAb it was at an 16:4 excess of the acceptor-labeled
antigen. Based on these data we chose to proceed with the donor-
and acceptor labeled antigens at equimolar concentrations, as the
differences were not remarkable in either way.
Effect of Incubation Time on Solution-phase Assay
Performance
Next, we studied the effect of incubation time on the formation
of TR-FRET signal. We were also interested in studying the
stability of the immune complexes formed in the homogenous
assay. The polyclonal IgG was cross-titrated with the fluorescent
antigens in a number of ratios, and the signals were measured at
several time points (15 min to 24 h) at room temperature (RT) or
4uC. As can be seen in Fig. 5, maximal TR-FRET values were
already seen at the earliest time point (15 min) after mixing.
Further incubation at 4uC for 2 h or overnight did not alter the
TR-FRET values (data not shown); however, at RT a decrease of
,15% was seen at 2 h that remained unaltered for 24 h (data not
shown).
Effects of Dissociating Agents
As immunoassays are often performed in the presence of protein
denaturants or detergents in low concentrations, to diminish
background, we tested the susceptibility of the homogenous assay
to urea and SDS. Again, the antibody in various concentrations
was mixed with the fluorescent antigens in the presence of low
concentrations of the two agents. As illustrated in Fig. 6, urea at up
to 2 M had little effect on the TR-FRET signal, which was
somewhat inhibited by SDS at 0.5%, yet not much at 0.25%.
Isolation and Characterization of the FRET-inducing
Complex
To estimate the sizes of the complexes responsible for the TR-
FRET signal, we separated them by sucrose gradient ultracentri-
fugation. Both the polyclonal and monoclonal anti-SA antibodies
were employed at 20 nM. With the former the fluorescent
antigens were used at 6.6 nM, and with the latter at 2.5 or
10 nM. The mixtures were separately ultracentrifuged, and the
fractions analyzed for TR-FRET activity and antibody as well as
sucrose concentration.
As shown in Fig. 7A–B, most of the FRET activity sedimented
in high-density fractions corresponding to relative molecular mass
(Mr) of 500 to.1000 kDa, when using MAb. In Fig. 7A (antibody
to antigen ratio 4:1) most of the MAb migrates in fractions that are
Figure 3. Antibody vs. antigen titration. A) Polyclonal anti-SA antibody (4.16 nM to 66.6 nM), B) polyclonal anti-GST antibody (2.08 nM to
33.3 nM) and C) monoclonal anti-SA antibody (4.16 nM to 66.6 nM) were mixed with five different concentrations of Eu-SA and AF647-SA (at
equimolar ratio), and resulting TR-FRET was measured. Dilution series of Fab fragments (7.5 nM to 120 nM) D) tested with 8 nM antigens (Eu-SA and
AF647-SA). The TR-FRET (expressed in response counts) is the average of two measurements. Raw data are presented on the left panel, and the
normalized data on the right panel. The concentration of specific IgG (for PAb), is indicated in brackets. Error bars are6 standard deviation calculated
from parallel wells.
doi:10.1371/journal.pone.0062739.g003
Figure 4. The effect of donor vs. acceptor concentration on the assay performance. A) Polyclonal anti-SA antibody (2.5 nM to 20 nM) was
mixed with Eu-SA (constant concentration of 4 nM) and AF647-SA (at concentrations from 1 nM to 16 nM). The TR-FRET values (expressed in
normalized response counts) were measured immediately after mixing. B) The same was done with the monoclonal antibody. The concentration of
specific IgG (for PAb), is indicated in brackets. Error bars are 6 standard deviation calculated from parallel wells.
doi:10.1371/journal.pone.0062739.g004
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not TR-FRET positive. On the other hand in Fig. 7B (antibody to
antigen ratio 1:1) most of the MAb migrates to fractions that are
TR-FRET positive. Thus the proportion of MAb brought into
these (TR-FRET-positive) high-density fractions depended on the
antigen to antibody ratio in the original MAb-SA mixture
(compare Fig. 7A to B). Furthermore, the results suggest that the
MAb to antigen ratio of 1:1 is close to optimal, since virtually no
free MAb was observed. Minor proportion of FRET signal was
observed in lower-density fractions corresponding to Mr of
,300 kDa.
Figs. 7C–D show the corresponding results using polyclonal
antibodies from two commercial sources. Interestingly, the TR-
FRET positive complexes generated by the two differed somewhat
in size. While the peak fractions in Fig. 7C correspond to Mr of
350 to 700 kDa, those in Fig. 7D resemble in size those obtained
using MAb (Fig. 7A–B). This difference between the two
immunoglobulin preparations may be due to a different propor-
tion of SA-specific antibody present in the two. Altogether, in the
homogenous solution-phase assay, most of TR-FRET signal
originated from immune complexes greater in size than a single
IgG+Eu-SA+AF647-SA (160 kDa+60 kDa+60 kDa=280 kDa).
However, a minor proportion of the signal came from immune
complexes of relatively small size range.
Two-step Solid-phase Assay
To further investigate the nature of FRET-pair formation, we
set up an assay wherein the formation of larger immune complexes
is prevented. Polyclonal anti-SA IgG (66.6 nM to 4.16 nM) was
Figure 5. The effect of incubation time on the TR-FRET values. The stability of the formed immune complexes was studied by mixing
polyclonal anti-SA antibody (4.16 nM to 66.6 nM) with Eu-SA and AF647-SA (at equimolar ratio from 0.5 nM to 8 mM). The TR-FRET values were
measured immediately after mixing the reagents (A) and after 2h incubation at rt (B). The concentration of specific IgG (for PAb), is indicated in
brackets. Error bars are 6 standard deviation calculated from parallel wells.
doi:10.1371/journal.pone.0062739.g005
Figure 6. The effect of dissociating agents on immune complex formation. Polyclonal anti-SA antibody (5 nM to 20 nM), Eu-SA and AF647-
SA were diluted A) to 0.05–0.5% SDS or B) to 0.25–2 M urea, mixed together and the TR-FRET values (expressed in normalized response counts) were
measured. The concentration of specific IgG (for PAb), is indicated in brackets. Error bars are 6 standard deviation calculated from parallel wells.
doi:10.1371/journal.pone.0062739.g006
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immobilized on microwells via protein A (Fig. 2C). After removal
of unbound antibodies the labeled antigens (Eu-SA and AF647-
SA; at 4 nM) were added, and TR-FRET was measured both
before and after removal of unbound antigens (M1 and M2 in
Fig. 8B). The TR-FRET signals were generated, in synchrony with
the IgG concentration, as in the solution-phase assay (Fig. 3), albeit
at a much lower level. Removing unbound and weakly bound
antigens lowered the signal considerably.
Single-step Solid-phase Assay
To further assess the performance characteristics of the solution-
phase and solid-phase assays, the polyclonal anti-SA (66.6 nM to
4.16 nM) and the labeled antigens (Eu-SA and AF647-SA; 4 nM)
were pipetted simultaneously onto protein A-coated microwells
(Fig. 2B). As in the two-step solid-phase assay, the TR-FRET
values were measured both before and after removal of unbound
IgG and antigens. While most of the signal was lost upon removing
unbound antigen-antibody complexes (M1 and M2 in Fig. 8A),
those remaining immobilized by protein A accounted for similar
TR-FRET values as two-step assay before unbound antigen
removal (Fig. 8B M1).While the signal levels were fairly low, the
background without specific antibody was only of a few counts,
achieving high signal to noise ratios with both solid phase assays.
Discussion
In this report we describe a novel TR-FRET based approach
for detection of antibodies from biological fluids using a solution-
phase homogenous assay and solid-phase heterogenous assays. We
demonstrated with donor- and acceptor-labeled SA that addition
of a specific antibody to a mixture of antigens each carrying one of
the two labels induces the formation of immune complexes
producing a TR-FRET signal promptly after combining the
reagents. Once formed the immune complexes appeared stable,
and even 24 h storage at 4uC did not markedly alter the TR-
FRET values. By antigen-antibody cross-titrations we observed the
assays to be applicable over a wide range of IgG concentrations.
We also studied the effects of dissociating agents on the immune
complex formation. Size-estimation by density gradient ultracen-
trifugation showed that most of the TR-FRET signal is derived
from large immune complexes (mw .500 kDa), while some signal
also emerged from smaller complexes (mw 250–400 kDa). Finally,
we set up a protein A based solid-phase assay to further investigate
the TR-FRET assay we have established.
We initially compared the sensitivity of detection of the TR-
FRET assay with that of ELISA. Furthermore, we used the ELISA
result to obtain an estimate of the amount of specific IgG in the
PAb. Even though the exact concentration of specific IgG
Figure 7. Size determination of immune complexes in density gradient ultracentrifugation. Immune complexes were formed by mixing
A) Monoclonal anti-SA, Eu-SA and AF647-SA at 8:1:1 ratio B) Monoclonal anti-SA, Eu-SA and AF647-SA at 2:1:1 ratio C) Polyclonal anti-SA (Abcam), Eu-
SA and AF647-SA at 3:1:1 ratio D) Polyclonal anti-SA (Springbioscience) at 3:1:1 ratio, and separated by ultracentrifugation in preformed 0–70%
sucrose gradient. Fractions collected from bottom were analyzed for TR-FRET activity, sucrose concentration and antibody concentration. The black
line represents relative TR-FRET value (each value divided by the highest measured value) and the dark grey line represents relative antibody
concentration (normalized to the highest value as above) in each fraction. Estimated molecular weight in kilodaltons (Y-axis) is calculated according
to each sucrose concentration (X-axis) and shown in light grey line. The second y-axis is a relative scale (from 0–100% of the TR-FRET in fraction with
highest TR-FRET signal) used for both TR-FRET signal and antibody amount.
doi:10.1371/journal.pone.0062739.g007
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molecules cannot be told through this assay, the result (25–30% of
specific IgG in the PAb) correlate with our TR-FRET assay data
in that, the maximum TR-FRET signal (peak) with PAb comes at
2 to 4 times higher antibody concentration than with MAb,
compare A and C in Fig. 3. The endpoint titration experiments in
ELISA also gave us the opportunity to compare the TR-FRET
assay with a conventional immunoassay. Obviously, the analytical
sensitivity of ELISA was higher (about 250 times) than that of the
TR-FRET assay, most likely due to the enzymatic reaction
inherent in the former. However, we feel the sensitivity of the TR-
FRET application to be sufficient for the assay to be applicable to
serodiagnostic use.
While varying the ratios of antigen to antibody, we observed the
TR-FRET values to increase in relation to the specific antibody
(mono- or polyclonal) concentrations. Yet, we observed that
beyond a peak (TR-FRET) signal, the values started to decline.
The most obvious explanation is a prozone effect in which only
one of the IgG molecule’s Fab arms attaches to an antigen, leaving
the other empty. Based on our original hypothesis (in which the
donor and acceptor are brought to close proximity via specific
IgG), the ideal molar ratio of the antigens and antibody could be
assumed to be 1:1:1 (donor:acceptor:IgG). However, the phenom-
enon in practise seems more complex.
According to the ultracentrifugation experiments (Fig. 7A to D),
the TR-FRET activity mostly derives from immune complexes of
various sizes, with both MAb and PAbs. With monoclonal anti-
SA, most of the TR-FRET signal originated from immune
complexes .700 kDa. Complexes of this size could include e.g.
three IgG molecules (ca. 450 kDa) and four antigen molecules (ca.
250 kDa). There was also some TR-FRET signal in density
gradient fractions that by molecular weight correspond to an
immune complex potentially containing one molecule of IgG and
donor-labeled and acceptor-labeled antigens. In all, it seems likely
that most of the TR-FRET signal does come from complexes
larger than one IgG plus two antigen molecules, as also suggested
by the solid-phase TR-FRET assay.
One point that needs to be taken into account is that the antigen
(SA) used in our experiments is a tetravalent molecule. One reason
why we initially chose this antigen is that it is commercially
available as both donor- and acceptor-fluorophore conjugates.
The tetrameric nature of SA in theory permits the attachment of
four IgG molecules (ca. 600–700 kDa) to one SA molecule (in the
case of a MAb). On the other hand, only steric considerations will
restrict the number of IgG molecules that potentially binds to a
single SA molecule. Thus to prove our initial hypothesis, one
would need a monovalent antigen and a monoclonal antibody. In
fact, the PAb in our TR-FRET assay actually yielded much higher
fluorescense counts than the MAb. The use of PAb seems to favor
the formation of bulky immune complexes responsible for TR-
FRET signals via non-covalent cross-linking of antigen molecules.
Since PAb recognizes a multiplicity of epitopes, it might allow
formation of tighter antigen-antibody complexes than a MAb thus
further explaining the higher TR-FRET values.
With the two-step solid-phase assay we further investigated the
nature of FRET-pair formation. By immobilizing anti-SA with
protein A and removing any unbound antibodies before the
addition of labeled antigens we prohibited the formation of larger
immune aggregates. A polyclonal IgG fraction usually contains
only a small portion (5–10%) of IgG molecules specific to the
antigen. Protein A, on the other hand, binds all IgGs regardless of
antigen specifity. Thus in the protein A bound antibody
population these specific antibodies very likely are too far from
each other to allow inter-antibody FRET-pair formation. Unfor-
tunately the polyclonal anti-SA we used seems to contain far too
many SA-specific antibodies for this hypothesis to hold true. In
future experiments it could be tested whether the low sensitivity of
this solid phase assay allows diluting our anti-SA with another
antibody, such as anti-GST, to significantly lower the portion of
Figure 8. Two-step and one-step solid-phase TR-FRET assays. A)
Polyclonal anti-SA antibody (at 66.6 nM to 4.16 nM) was pipetted with
antigen mixture (Eu-SA and AF647-SA; 4 nM) onto microwells coated
with protein A. The TR-FRET was measured directly after incubation
(M1) and after replacing the reaction solution with TBS (M2). The M2
values are also represented separately. B) Polyclonal anti-SA antibody
(66.6 nM to 4.16 nM) was immobilized via protein A onto a 384-well
plate and excess antibodies were removed prior to adding the antigen
mixture (Eu-SA and AF647-SA, both at 4 nM final concentration). TR-
FRET was measured directly after incubation (M1) and after replacing
the antigen mixture with TBS (M2). The concentration of specific IgG
(for PAb), is indicated in brackets. Error bars are 6 standard deviation
calculated from parallel wells.
doi:10.1371/journal.pone.0062739.g008
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SA-specific IgGs. These results together with the single-step solid-
phase assay show that TR-FRET –based applications are viable in
many different setups.
Liu et al. [9] introduced a homologous immunoassay based on
two-photon excitation fluorescence resonance energy-transfer
(TPE-FRET). They detected polyclonal anti-BSA antibodies using
differentially labeled BSA molecules. Their results are in line with
ours on SA and anti-SA, although the techniques are somewhat
different. We also verified the phenomenon using a monoclonal
antibody. It is not impossible that also their results are based on
larger immune complexes, as they did not assess in detail the
molecular determinants of their findings. It should nevertheless be
taken into account that BSA is a monomer at the concentrations
used in the study implying that the FRET-bridge assay should be
applicable with monomeric antigens. On the other hand, we wish
to pinpoint that most of the microbial antigens do naturally exist as
multimers (di- or trimers or larger).
The homogenous TR-FRET immunoassay set up herein is
rapid and robust, and flexible in terms of incubation time and
temperature. After this demonstration of proof-of-concept, in the
future we plan to label diagnostic antigens with donor and
acceptor fluorophores, and to experimentally demonstrate that the
assay is applicable to wash-free human serodiagnostics. Notably,
the average concentrations of IgG antibodies detected in human
sera (,4–16 mg/ml of which antibody of particular specificity
comprises only a few percent) are even higher than those used in
our experiments. The solution-phase TR-FRET based immuno-
assay principle presented herein has potential to emerge as a major
approach in diagnostic antibody detection.
Supporting Information
Figure S1 Fragmentation of anti-streptavidin MAb. The
lanes in SDS-PAGE are: 1. marker (Precision Plus ProteinTM Dual
Color Standards, Bio-Rad), 2. blank, 3. Gammabind beads (the Fc
parts), 4. concentrated Fab fragments, 5. unused Gammabind
beads, 6. intact anti-streptavidin MAb. The molecular mass
markers (visible on gel) are 250 kDa, 150 kDa, 100 kDa, 75 kDa,
50 kDa and 37 kDa by size.
(TIF)
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